Back to today’s briefing

Story perspectives

Keytruda's $130B Success Faces Rivals in Lung Cancer

2/17/2025

45 6

Summary

Story summary

Keytruda, Merck's groundbreaking cancer immunotherapy, has amassed a staggering $130 billion in sales since its debut in 2014, with $29.5 billion earned just last year. Meanwhile, a promising experimental drug for non-small-cell lung cancer is showing remarkable results, nearly doubling patient survival without disease progression to 11.1 months, outpacing Keytruda's 5.8 months.

1 of 1

Story summary

Keytruda, Merck's groundbreaking cancer immunotherapy, has amassed a staggering $130 billion in sales since its debut in 2014, with $29.5 billion earned just last year. Meanwhile, a promising experimental drug for non-small-cell lung cancer is showing remarkable results, nearly doubling patient survival without disease progression to 11.1 months, outpacing Keytruda's 5.8 months.